The UK manufacturing arm of Toyota has warned “the road ahead may be challenging” after its profit slumped by more than £100m during its latest financial year. The division of …
Retirement Planning
The Debate: Should you get drunk at the Christmas work party?
Should you get drunk at the office Christmas party? It’s a question as old as time. We get the case for and against in this week’s Debate YES: Sometimes you …
The Debate: Should you get drunk at the Christmas work party?
Should you get drunk at the office Christmas party? It’s a question as old as time. We get the case for and against in this week’s Debate YES: Sometimes you …
Weight-loss drugs ‘fundamentally changing’ the way Brits eat
The rise of weight-loss drugs is starting to affect supermarket sales, with experts warning that the sector is unprepared for the change this Christmas. More than one in ten Brits …
Weight-loss drugs ‘fundamentally changing’ the way Brits eat
The rise of weight-loss drugs is starting to affect supermarket sales, with experts warning that the sector is unprepared for the change this Christmas. More than one in ten Brits …
Forget retail stores – watch collectors now hang at the clubhouse
Just past De Beers on London’s Old Bond Street lies an anonymous-looking door. Look through to the lobby beyond it and you’d be forgiven for thinking it was an office …
Forget retail stores – watch collectors now hang at the clubhouse
Just past De Beers on London’s Old Bond Street lies an anonymous-looking door. Look through to the lobby beyond it and you’d be forgiven for thinking it was an office …
Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocarcinoma1
For United Kingdom (UK) Trade and Medical Media Only Taiho Oncology Europe GmbH announced today the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor.1,3 …
Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocarcinoma1
For United Kingdom (UK) Trade and Medical Media Only Taiho Oncology Europe GmbH announced today the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor.1,3 …
TITAN Honored With ESG Transparency Award 2025 for Excellence in Disclosure
TITAN Group (Brussels:TITC) has been recognized for setting a benchmark in transparent ESG reporting, earning the prestigious ESG Transparency Award 2025 from the EUPD Group, Europe’s leading market research institute. …